echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Will biopharmaceuticals and traditional Chinese medicines be included in the national collection? These varieties have been ahead of the way!

    Will biopharmaceuticals and traditional Chinese medicines be included in the national collection? These varieties have been ahead of the way!

    • Last Update: 2020-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The third batch of national collection is in full swing, but today's National Health Insurance Administration a short message caused a stir in the industry.
    biological products and traditional Chinese medicine officially entered the national field of view, a storm will befall these two hundred billion markets? The progress of national collection has broken through the imagination! While the industry is still discussing the third batch of collection varieties and injection consistency evaluation, the State Health Insurance Administration announced on July 17 thinly publicly that a symposium on the centralized procurement of biological products (including insulin) and traditional Chinese medicine was held on July 15-16, listened to expert opinions and suggestions, studied and improved procurement policies in related areas, and will promote the reform of procurement methods.
    just over 70 words of news, revealing the next direction for policymakers: biologics and traditional Chinese medicine.
    01 there is little left of the evaluation of chemical drugs Although the third batch of official documents of national collection has not yet been released, but the local on the third national collection of the document exposure, according to the relevant documents, the third batch of national collection and collection of the volume of the catalog involving a total of 52 varieties, 86 product regulations, compared to the first round of 25 varieties, the second round of the collection of 33 varieties again expanded.
    in fact, the remaining range of options is not very large in the range of chemical drugs, after being harvested through three batches of national collections.
    as of mid-May, 832 standards have passed the consistency evaluation, of which 80 standards have three or more enterprises have been evaluated, excluding the first batch of 25 varieties and the second batch of 33 varieties, a total of 58 varieties have two and above enterprises through consistency evaluation, and the vast majority of these 58 varieties are likely to appear in the final collection of the third batch of national collection.
    thus, the third batch of collection catalog was finalized, in the short term over the evaluation of the three varieties have not been much, the national collection of eyes naturally look edifice and biological products into the market's huge.
    but traditional Chinese medicine, biological products generally do not exist consistency evaluation, that is, commonly referred to as "collecting tickets", and there are exclusive varieties, dosage forms and other complex factors, how to carry out national collection in the future will be the focus of the industry.
    02 Some areas have been the first, however, regardless of whether the national harvest will eventually be included in traditional Chinese medicine and biological products, the local has already first tried, will be Traditional Chinese medicine, insulin and so on pulled into the local collection battlefield.
    for example, Jinhua City and Qinghai Province in the collection of traditional Chinese medicine has appeared, and a few years ago Wuhan's insulin collection has also been because of the "soul cut price" brush screen.
    but different from the existence of consistent evaluation of chemical drugs, chinese traditional medicine and biological products how to collect people reverie.
    to Jinhua City, for example, the city's second batch of volume procurement included a total of 180 Chinese medicine, of which 33 are low-cost drugs (8 exclusive varieties), including oral, injection, paste and other dosage forms; first of
    , Jinhua City made a mandatory provision for the reduction of prices, with the general name of the same product regulations containing low-cost drugs of traditional Chinese medicine set a maximum price, on the basis of the maximum price, the price reduction shall not be less than 10%, of which the exclusive enterprise production of traditional Chinese medicine is a low-cost medicine, the price reduction shall not be less than 20%.
    other traditional Chinese medicines in the current Zhejiang Province medical insurance payment standards, the price reduction should not be less than 20%.
    this means that in addition to non-exclusive low-cost drugs, most traditional Chinese medicines, especially exclusive varieties, need to reduce prices by at least 20%.
    , the four dimensions of usage, price, decline, and expert review are evaluated.
    at the same time, in order to encourage enterprises to reduce prices, Jinhua City has made a series of restrictions on the unselected varieties, such as encouraging buyers to choose high-quality low-cost alternative drugs, requiring a reduction of 50% of the estimated annual use of non-selected drugs procurement.
    Jinhua City's procurement policy for Traditional Chinese medicine exceeded many people's expectations, but also attracted a lot of controversy.
    03 super 75% waste standard Jinhua City included in the 180 common traditional Chinese medicine, there is no shortage of Qingkailing particles, ginseng wheat injection, dewind detoxified capsules and pedi-blue anti-inflammatory oral liquid and other large varieties, but in the end only a few varieties such as compound dansan tablets, six-flavored yellow pills, strong dew and so on have been selected in the enterprise.
    According to the second batch of selected products released on June 24 in Jinhua City, only 39 of the 180 traditional Chinese medicine drugs were initially announced, with a winning rate of only 21.7%.
    in these areas of traditional chinese medicine collection, especially some exclusive varieties, only price reduction should be marked and abandoned two options, and this is behind the enterprise's concern about price linkage: once selected varieties appear the lowest price in the country, it will lead to a series of price cuts in the market, because of the market share, resulting in the national market are facing price reduction, and ultimately may not be worth the loss.
    thus, in Jinhua's second batch of collection soon after, on the news of the suspension of municipal collection, some provincial health insurance bureau issued relevant documents.
    and the National Health Insurance Administration for traditional Chinese medicine and biological agents collection of the symposium, may be intended to the relevant varieties of collection income countries.
    and Qinghai province took a different approach.
    in short, the variety of manufacturers according to quotation, enterprise reputation, product quality and other comprehensive factors ranking, the highest score of the selection;
    this is the test of manufacturers, can combine the adaptation certificate, functional efficacy and other aspects to give experts less price reduction or even not reduce the price reasons, otherwise once the bargaining failure, will be scrapped.
    04 Biologics are gradually "mature" and biologics include not only insulin, but also blood products, vaccines, monotophosandes and so on.
    before, Wuhan City on insulin collection, insulin is also considered to have sufficient "conditions" to enter the country to harvest the varieties.
    and biosimilars are another area that is seen as having the potential to enter the country.
    February 2019, fuhong Hanxuan's Litoxisimonoantitic injection (Hanlikang) was launched, the first "domestic" biologically similar drug in China. After
    , The Adamu sing-ire injection (Gleli), Haizheng's Adamu sing-in injection (Anjianin), Qilu's Beva Zhuszsing mono-injection (Anda) and Cinda's Beva Zhussing (DaYuTong) were all approved for listing in the past two years.
    Although the industry had predicted that biosimilars would be included in the third batch of collections, but now it appears that the forecast is frustrated, but in the fourth batch of collection, biosimilars are still a popular candidate.
    in addition to the five varieties approved above, as of the end of last year, There are about 391 biosimilar drugs in China, the main targets include CD20, EFGR, VEGF, TNF, RANKL, HER2, etc., involving rituximatod, qutodzumab, bevalzumab, Adamu monoidatis and more than 50 original research drugs.
    only Adamu mono-resistance this variety, there are hundred Satoa, Haizheng Pharmaceuticals, Cinda Bio, Fuhong Hanxuan, Junshi biological, Tonghua Dongbao, Shenzhou cells and other about 20 enterprises research and development, layout of Thelitoxi monophonic enterprises have Fuhong Hanxuan , Haizheng Pharmaceuticals, Cinda Bio, Zhengda Qing, Jiahe Biology, Shanghai Biology, etc. , while the layout of Qutozhu monobtant enterprises have Zhengda Qing, Jiahe Bio, Fuhong Hanxuan, Haizheng Pharmaceuticals, Qilu Pharmaceuticals and other enterprises.
    reports predict that 30 biosimilars are expected to be approved for sale in China in the next three years, 6 in 2020, 11 in 2021 and 13 in 2022.
    and it's all paving the way for the country to collect.
    but now, many biologically similar drug research products through national negotiations into health insurance, experienced a sharp reduction in prices, domestic similar drugs on the market at the beginning of the market will face a sharp price reduction, from fuhong Hanxuan, Cinda and other enterprises pricing, similar drug pricing in the original research after the price reduction of 7-8 fold, and in the future, if included in the collection, in the face of relatively higher research and development costs, similar pharmaceutical enterprises will face a double policy.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.